ARGX:NSD-argenx NV ADR (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 646.64

Change

0.00 (0.00)%

Market Cap

USD 40.41B

Volume

0.20M

Analyst Target

USD 254.56
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-09 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 115.69B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 53.25B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 40.16B
ONC BeiGene, Ltd.

N/A

USD 27.70B
RPRX Royalty Pharma Plc

N/A

USD 18.35B
INSM Insmed Inc

N/A

USD 17.98B
SMMT Summit Therapeutics PLC

N/A

USD 13.53B
INCY Incyte Corporation

N/A

USD 13.31B
EXEL Exelixis Inc

N/A

USD 11.39B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 10.98B

ETFs Containing ARGX

DXID:CA Dynamic Active Innovation.. 4.55 % 0.00 %

N/A

CAD 0.03B
HEAL:SW iShares Healthcare Innova.. 2.78 % 0.00 %

N/A

USD 1.05B
XSDR:LSE Xtrackers MSCI Europe Hea.. 2.67 % 0.00 %

N/A

USD 0.21B
FCSI:CA Franklin ClearBridge Sust.. 2.09 % 0.00 %

N/A

CAD 4.71M
EQQJ:XETRA Invesco NASDAQ Next Gener.. 1.37 % 0.00 %

N/A

USD 0.05B
TEET:SW 1.36 % 0.00 %

N/A

N/A
TEGB:LSE VanEck Sustainable Europe.. 1.25 % 0.00 %

N/A

N/A
AGED:SW iShares Ageing Population.. 0.61 % 0.00 %

N/A

N/A
TSWE:LSE VanEck Sustainable World .. 0.49 % 0.00 %

N/A

N/A
BBH VanEck Biotech ETF 0.00 % 0.35 %

N/A

USD 0.33B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

N/A

USD 0.04B
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

N/A

N/A
AGED:LSE iShares Ageing Population.. 0.00 % 0.00 %

N/A

N/A
AGES:LSE iShares IV Public Limited.. 0.00 % 0.00 %

N/A

N/A
DRDR:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

N/A
HEAL:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

N/A
HLTH:LSE SPDR® MSCI Europe Health.. 0.00 % 0.00 %

N/A

N/A
STW:PA SPDR® MSCI Europe Health.. 0.00 % 0.00 %

N/A

USD 0.66B
2B70:F iShares NASDAQ US Biotech.. 0.00 % 0.00 %

N/A

USD 0.52B
DXSE:F Xtrackers Stoxx Europe 60.. 0.00 % 0.00 %

N/A

N/A
EXV4:F 0.00 % 0.00 %

N/A

N/A
SPYH:F SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

N/A

N/A
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

USD 0.52B
2B77:XETRA iShares Ageing Population.. 0.00 % 0.00 %

N/A

USD 0.50B
2B78:XETRA iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

USD 1.05B
DXSE:XETRA Xtrackers - Stoxx Europe .. 0.00 % 0.00 %

N/A

USD 0.14B
EXV4:XETRA iShares STOXX Europe 600 .. 0.00 % 0.00 %

N/A

USD 0.70B
SPYH:XETRA SPDR® MSCI Europe Health.. 0.00 % 0.00 %

N/A

N/A
TSWE:XETRA VanEck Sustainable World .. 0.00 % 0.00 %

N/A

N/A
V3ET:XETRA VanEck Sustainable Europe.. 0.00 % 0.00 %

N/A

N/A
BMED BlackRock Future Health E.. 0.00 % 0.00 %

N/A

USD 2.84M
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.00 %

N/A

USD 0.04B
2B77:F iShares Ageing Population.. 0.00 % 0.00 %

N/A

N/A
2B78:F iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

N/A
ESIH:F Ishares VI PLC - Ishares .. 0.00 % 0.00 %

N/A

N/A
ESIH:XETRA iShares MSCI Europe Healt.. 0.00 % 0.00 %

N/A

N/A
HEAE:LSE SPDR® MSCI Europe Health.. 0.00 % 0.00 %

N/A

N/A
STWX:SW SPDR® MSCI Europe Health.. 0.00 % 0.00 %

N/A

USD 0.66B
SXDPEX:SW iShares STOXX Europe 600 .. 0.00 % 0.00 %

N/A

USD 0.44B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.14% 70% C- 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.14% 70% C- 70% C-
Trailing 12 Months  
Capital Gain 61.06% 85% B 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 61.06% 85% B 87% B+
Trailing 5 Years  
Capital Gain 310.41% 97% N/A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 310.41% 97% N/A 95% A
Average Annual (5 Year Horizon)  
Capital Gain 24.99% 68% D+ 77% C+
Dividend Return 24.99% 68% D+ 77% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 30.31% 86% B+ 61% D-
Risk Adjusted Return 82.45% 99% N/A 92% A
Market Capitalization 40.41B 100% F 97% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector